Withdrawal Symptoms after Serotonin-Noradrenaline Reuptake Inhibitor Discontinuation: Systematic Review

@article{Fava2018WithdrawalSA,
  title={Withdrawal Symptoms after Serotonin-Noradrenaline Reuptake Inhibitor Discontinuation: Systematic Review},
  author={Giovanni Andrea Fava and Giada Benasi and Marcella Lucente and Emanuela Offidani and Fiammetta Cosci and Jenny Guidi},
  journal={Psychotherapy and Psychosomatics},
  year={2018},
  volume={87},
  pages={195 - 203}
}
Background: Serotonin-noradrenaline reuptake inhibitors (SNRI) are widely used in medical practice. Their discontinuation has been associated with a wide range of symptoms. The aim of this paper is to identify the occurrence, frequency, and features of withdrawal symptoms after SNRI discontinuation. Methods: PRISMA guidelines were followed to conduct a systematic review. Electronic databases included PubMed, the Cochrane Library, Web of Science, and MEDLINE from the inception of each database… 
Neonatal Withdrawal Syndrome following Late in utero Exposure to Selective Serotonin Reuptake Inhibitors: A Systematic Review and Meta-Analysis of Observational Studies
TLDR
The present work provides a framework for the identification of neonatal SSRI withdrawal syndrome and suggests tapering and discontinuation of antidepressant drugs before and during the early phase of pregnancy are worth attempting to prevent the occurrence of this syndrome.
Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
TLDR
The present overview aimed at analyzing the literature to illustrate withdrawal after decrease, discontinuation, or switch of psychotropic medications based on the drug class, finding that benzodiazepines should be substituted by medications that cause less dependence such as antidepressants and antipsychotics runs counter the available literature.
Discontinuing Psychotropic Drugs from Participants in Randomized Controlled Trials: A Systematic Review
TLDR
RCTs use drug discontinuation to study several key issues in psychopharmacology but infrequently justify how they implement it or acknowledge that possible withdrawal symptoms may threaten internal validity, so reappraising the use of drug discontinuations and the recognition of withdrawal symptoms in RCTs is required.
A Paradigmatic Case of Postselective Serotonin Reuptake Inhibitors Sexual Dysfunction or Withdrawal After Discontinuation of Selective Serotonin Reuptake Inhibitors?
encephalitis, the patient received metilprednisolone and immunoglobulin. One week after immunotherapy, she continued with severe signs of deliriumand excited catatonia, despite treatment with
Understanding and Managing Withdrawal Syndromes After Discontinuation of Antidepressant Drugs.
TLDR
Alternative strategies that do not encompass continuation of antidepressant treatment are required, but there is currently lack of adequate research for guiding the clinical approach.
Off-label Antidepressant Use for Treatment and Management of Chronic Pain: Evolving Understanding and Comprehensive Review
TLDR
The use of antidepressants offers alternative and adjunctive therapy options for patients suffering from chronic pain from various modalities, and TCAs, mono-amine oxidase inhibitors, selective serotonin receptor inhibitors, SNRIs, and atypical antidepressants have been shown to have analgesic and sometimes antiinflammatory capabilities that are independent of their mood-stabilizing effects.
Benzodiazepine withdrawal in older people: what is the prevalence, what are the signs, and which patients?
TLDR
It is assumed that withdrawal symptoms in patients with chronic use play an essential role in the nonstop use of BZD/Z-drugs.
The ‘patient voice’: patients who experience antidepressant withdrawal symptoms are often dismissed, or misdiagnosed with relapse, or a new medical condition
TLDR
Although the patients captured in this analysis might represent medication withdrawal experiences that are more severe than average, they highlight the current inadequacy of health care systems to recognise and manage prescribed drug withdrawal, and patient feedback in general.
Outcome of antidepressant drug discontinuation with taperingstrips after 1–5 years
TLDR
The evidence-based approach of personal tapering to counter withdrawal, as used for drugs causing withdrawal, may represent a simple solution for an important antidepressant-related public health problem, without extra costs.
Development of Obsessive-Compulsive Symptoms Following Abrupt Discontinuation of Venlafaxine
TLDR
The development of OCS (obsessional suicidal thoughts) is reported in a patient with major depressive disorder and absence of a previous obsessive-compulsive disorder following abrupt discontinuation of venlafaxine and treatment with escitalopram facilitated remission.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 89 REFERENCES
Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review
TLDR
Clinicians need to add SSRI to the list of drugs potentially inducing withdrawal symptoms upon discontinuation, together with benzodiazepines, barbiturates, and other psychotropic drugs.
A review of the management of antidepressant discontinuation symptoms
TLDR
The available literature on the best methods of discontinuation for antidepressants in order to avoid or prevent the occurrence of any unpleasant side effects associated with antidepressant withdrawal is reviewed, highlighting the lack of controlled data to support the available guidelines.
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
TLDR
Abrupt interruption of antidepressant therapy for 5-8 days was associated with the emergence of new somatic and psychological symptoms in patients treated with paroxetine and to a lesser degree sertraline, with few symptoms seen with fluoxetines.
Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms.
TLDR
SERTraline and venlafaxine XR demonstrated comparable effects on QOL and efficacy in treatment of major depression, although sertraline may be associated with a lower symptom burden during treatment discontinuation and a reduced risk of blood pressure increase.
The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: a randomised study.
TLDR
It is suggested that there is little advantage to a two-week taper over a three-day taper when switching antidepressants and the importance of half-life in determining discontinuation symptoms is supported.
New Classification of Selective Serotonin Reuptake Inhibitor Withdrawal
TLDR
Withdrawal from SSRIs and other CNS drugs produces psychiatric symptoms that can be confounded with true relapse or recurrence of the original illness, and withdrawal symptoms must be identified to avoid prolonging treatment or giving unnecessarily high doses.
Duloxetine Does Not Relieve Painful Physical Symptoms in Depression: A Meta-Analysis
  • G. Spielmans
  • Medicine, Psychology
    Psychotherapy and Psychosomatics
  • 2007
TLDR
Based upon the currently available evidence, the marketing of duloxetine as an antidepressant with analgesic properties for people with depression does not appear to be adequately supported.
Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.
TLDR
Duloxetine is efficacious for the treatment of major depressive disorder and is well tolerated and safe, and insomnia and asthenia were the only adverse events reported statistically significantly (p < .05) more frequently by duloxettine-treated patients compared with placebo- treated patients.
A comparative study of milnacipran and paroxetine in outpatients with major depression.
TLDR
Both milnacipran and paroxetine were effective and well tolerated by outpatients with major depression treated for 6 weeks and after treatment discontinuation milncipran was associated with less emergent symptoms.
Benefits and harms in clinical trials of duloxetine for treatment of major depressive disorder: comparison of clinical study reports, trial registries, and publications
TLDR
Clinical study reports should be used as the data source for systematic reviews of drugs, but they should first be checked against protocols and within themselves for accuracy and consistency.
...
1
2
3
4
5
...